Biotechnology company developing treatments for obesity and cardiometabolic diseases
Biotechnology company developing treatments for obesity and cardiometabolic diseases. Its research targets activin type II receptors and combines activin biology with incretin biology to influence fat and muscle metabolism, improve body composition, and address metabolic health. Versanis was acquired by Eli Lilly, which is studying its therapeutic approach alone and alongside incretin-based medicines.